In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl⁺ Neoplastic Cells

^{1 1}Department of Clinical Medicine, S. Gerardo Hospital-University of Milano-Bicocca, Monza, Italy; ²Department of Oncology, Wyeth Research, Pearl River, New York; ³Department of Experimental Oncology, National Cancer Institute, Milan, Italy; ⁴Department of Biological Chemistry and Centro Interdipartimentale di Ricerca e Servizi per le Biotecnologie Innovative, National Research Centre, Institute of Neuroscience, University of Padova, Padova, Italy; ⁵Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland; and ⁶Department of Oncology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada

^* To whom correspondence should be addressed. E-mail: carlo.gambacorti{at}unimib.it.

	Abstract

Resistance to imatinib represents an important scientific and clinical issue in chronic myelogenous leukemia. In the present study, the effects of the novel inhibitor SKI-606 on various models of resistance to imatinib were studied. SKI-606 proved to be an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines and transfectants, with IC₅₀ values in the low nanomolar range, 1 to 2 logs lower than those obtained with imatinib. Cells expressing activated forms of KIT or platelet-derived growth factor receptor (PDGFR), two additional targets of imatinib, were unaffected by SKI-606, whereas activity was found against PIM2. SKI-606 retained activity in cells where resistance to imatinib was caused by BCR-ABL gene amplification and in three of four Bcr-Abl point mutants tested. In vivo experiments confirmed SKI-606 activity in models where resistance was not caused by mutations as well as in cells carrying the Y253F, E255K, and D276G mutations. Modeling considerations attribute the superior activity of SKI-606 to its ability to bind a conformation of Bcr-Abl different from imatinib. (Cancer Res 2006; 66(23): 11314-22)

Key Words: SKI-606, CML, Bcr-Abl, tyrosine kinase inhibitor, resistance to imatinib